Aarti Drugs Limited (NSE:AARTIDRUGS)

India · Delayed Price · Currency is INR

343.25

+2.95 (0.87%)

Apr 1, 2025, 3:29 PM IST

-20.96% (1Y)

Market Cap	31.24B
Revenue (ttm)	23.30B
Net Income (ttm)	1.53B
Shares Out	n/a
EPS (ttm)	16.69
PE Ratio	20.47
Forward PE	n/a
Dividend	1.00 (0.29%)
Ex-Dividend Date	Feb 4, 2025

Volume	197,242
Average Volume	210,958
Open	340.00
Previous Close	340.30
Day's Range	338.10 - 347.60
52-Week Range	330.05 - 635.00
Beta	0.88
RSI	41.56
Earnings Date	Apr 30, 2025

About Aarti Drugs

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, ti... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1984

Employees 1,064

Stock Exchange National Stock Exchange of India

Ticker Symbol AARTIDRUGS

Full Company Profile

Financial Performance

In 2023, Aarti Drugs's revenue was 25.29 billion, a decrease of -6.90% compared to the previous year's 27.16 billion. Earnings were 1.71 billion, an increase of 3.07%.

Financial Statements

News

Aarti Drugs receives US FDA clearance, removed from Import Alert 66-40

Aarti Drugs Limited announced that it has successfully been removed from the United States Food and Drug Administration (US FDA) Import Alert 66-40, paving the way for the company to resume exports to...

6 weeks ago - Business Upturn

Aarti Drugs Ltd (BOM:524348) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline with ...

Aarti Drugs Ltd (BOM:524348) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic Investments and Operational Efficiency

2 months ago - GuruFocus

Aarti Drugs shares surge despite Q3 FY25 EBITDA margin falls to 11.1%

Aarti Drugs Limited saw its shares rise 1.34% to ₹402.00 following the announcement of its Q3 FY25 financial results. The company reported a 1.1% year-on-year (YoY) growth in consolidated net profit, ...

2 months ago - Business Upturn

Aarti Drugs Q3 FY25 results: Revenue down 8% to Rs 556.6 crore, Net Profit flat at Rs 37.09 crore

Aarti Drugs Limited has announced its consolidated financial results for Q3 FY25, reporting revenue from operations of ₹556.6 crore, marking a YoY decline of 8.1% from ₹606.94 crore in Q3 FY24 and a Q...

2 months ago - Business Upturn

Aarti Drugs shares surge 15% after receiving EIR from USFDA for API plant in Tarapur

Aarti Drugs Limited witnessed a 15% surge in its stock price after receiving the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA). The EIR pertains to ...

3 months ago - Business Upturn

Aarti Drugs shares fall over 2% following poor Q2 FY25 results

Aarti Drugs witnessed a decline of over 2% in its share price following the release of its financial results for the second quarter of FY25. The company’s performance showed a noticeable drop in both ...

5 months ago - Business Upturn

Aarti Drugs stock in focus as Q2 FY25 results show 6.3% revenue decline to ₹543.09 crore; profit falls 12.1% YoY to ₹40.99 crore

Aarti Drugs Limited has announced its financial results for the second quarter of FY25, reporting a decrease in both revenue and profit compared to the same period in the previous year. Key Financial ...